Basal cell carcinoma (BCC) is the most common form of skin malignancy worldwide, and accounts for about 80% of all nonmelanoma skin cancers [
1,
2]. Vismodegib, an oral sonic hedgehog signaling pathway inhibitor, has recently been approved by the Food and Drug Association for the treatment of locally advanced, metastatic, and recurrent basal cell carcinomas that are ineligible for surgery or radiotherapy [
4]. Several studies have demonstrated the efficacy and safety of this small molecule which selectively connects to the Smoothened protein and blocks intracellular signaling, deactivating the hedgehog pathway and thus inhibiting tumor growth [
7]. As reported in our results, muscle spasms, dysgeusia, weight loss, and alopecia are the most frequently described adverse events associated with vismodegib therapy. The timing and grade of severity of these events vary, but they affect patient quality of life and sometimes lead to treatment discontinuation [
8]. The majority of our patients reported that mild to moderately severe AEs (grade 1 or 2) occurred in the first two months of therapy, except for alopecia, which occurred later and was almost always a severe event. In recent years, different dose reduction strategies during routine treatment have been proposed as a means to reduce AE severity and achieve the optimum duration of vismodegib treatment. Transitioning from a continuous to an intermittent regimen could be a way to avoid dropouts [
9,
10]. NMSC also has an appreciable impact on patient QOL, especially for the locally advanced and the metastasizing forms of BCC, due to the symptomatology involved and the potential for physical disfigurement, which usually compromises the psychological state of the patient [
11]. In the present study, the mean overall DLQI score across 41 patients decreased from 5.7 at the baseline visit to 0.4 after 6 months of treatment, indicating that vismodegib had a positive effect on patient HRQOL according to Finlay and Khan [
6]. The mean DLQI score (maximum possible score: 30) in a normal population usually ranges from 0 to 0.5 [
12]. Two other studies have used the DLQI test to assess HRQOL in patients with BCCs who were treated with surgery, and those studies observed a significant decrease in DLQI score 3 months after surgery [
13,
14]. Moreover, in 2012, a clinical study involving 25 patients with advanced BCCs who were treated with X-ray therapy showed a significant decrease in DLQI score to a normal level 3 months after treatment (from 1.2 ± 1.5 to 0.4 ± 0.9) [
15]. In the literature, data on HRQOL in patients with advanced BCCs who were treated with vismodegib are limited. A phase 2 study of vismodegib safety, STEVIE (NCT01367665), reported the HRQoL outcomes in 730 patients with locally advanced BCCs and metastasizing BCCs. Skindex-16 and MD Anderson Symptom Inventory (MDASI) questionnaires were completed at baseline and at three subsequent visits, and the results pointed to an improvement in HRQoL in all vismodegib-treated patients [
16]. Furthermore, in a recent study, Gualdi et al. used a different test—the Pictorial Representation of Illness and Self Measure (PRISM)—to assess HRQoL in 10 patients treated with vismodegib, which was evaluated as the Self-Illness Separation (SIS) score. The authors reported that the average SIS score was inversely correlated to the average number of AEs, which tended to increase during the intermittent therapeutic regimen [
17]. To the best of our knowledge, this is the first study to demonstrate a significant change in patient health-related quality of life from baseline to 6 months after hedgehog pathway inhibitor therapy initiation using the DLQI test. A significant decrease in the overall DLQI score was found, especially for the subcategory “symptoms and feelings,” which significantly decreased from baseline to 6 months after treatment initiation, despite the occurrence of multiple AEs. Interestingly, although patients with BCCs in visible areas such as the face or neck presented a higher DLQI score at the baseline visit than patients with BCCs on the trunk and legs, the scores for the two groups were very similar after 6 months of vismodegib therapy. A number of authors argue that the DLQI may not be specific enough to accurately evaluate the quality of life in patients with basal cell carcinomas, as this kind of questionnaire is tailored to patients with chronic skin conditions such as eczema or psoriasis. This could indicate the need for a more disease-specific instrument that is validated for use in non-English-speaking countries [
18].